Advertisement

Related Videos

Welcome and Introduction to Vi3C

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

The Interventional Pharmacoeconomic Toolbox Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Sep
02
Today In Oncology
Spartalizumab-Based Triplet Improves Long-Term Overall Survival in BRAF V600–Mutant Melanoma
ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
Sociological Study Explores the Concept of ‘Temporal Misalignment’ Among Patients With Terminal Cancer
MD Anderson President Announces Retirement, Shares Leadership Transition Plans
High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo